LOGIN  |  REGISTER
Chimerix
Viking Therapeutics

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

May 21, 2025 | Last Trade: US$1.40 0.14 11.11

SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia’s CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals at A.G.P., on May 21, 2025.

Dr. Altman will share recent business developments on the Company’s therapeutic development pipeline with a focus on its lead CardiAMP autologous cell therapy for the treatment of ischemic heart failure.

Fireside Chat Details:
Date: Wednesday, May 21, 2025
Time: 03:40 p.m. EDT
Speaker: Peter Altman Ph.D., CEO
Moderator: Jim Molloy, AGP Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals
Webcast: https://us02web.zoom.us/webinar/register/WN_jB1HgKLvQFmUfC6VBT11mw

About BioCardia®

BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit www.biocardia.com.

C4 Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page